triptonide has been researched along with Prostatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Feng, H; Li, Y; Tang, H; Xu, H | 1 |
| Chen, L; Chen, M; Dong, F; Jiang, M; Sun, W; Wang, A; Wang, R; Yang, P; Zhang, C; Zhang, Y | 1 |
2 other study(ies) available for triptonide and Prostatic Neoplasms
| Article | Year |
|---|---|
Semisynthesis of triptolide analogues: effect of B-ring substituents on cytotoxic activities.
Topics: Antineoplastic Agents; Cell Proliferation; Diterpenes; Drug Screening Assays, Antitumor; Epoxy Compounds; Glioma; Humans; Male; Models, Molecular; Molecular Structure; Organic Chemicals; Phenanthrenes; Prostatic Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2014 |
Triptonide acts as a novel antiprostate cancer agent mainly through inhibition of mTOR signaling pathway.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; Male; Mice; Mice, Nude; Prostate; Prostatic Neoplasms; Signal Transduction; TOR Serine-Threonine Kinases; Triterpenes | 2019 |